Recruiting of MP1032's Phase IIa trial in psoriasis successfully completed
Zurich, October 25, 2016. MetrioPharm AG announces that dosing of the last patient in the clinical phase IIa trial MP1032-CT02 was started on October 20, 2016. The enrolment of the last patient marks the successful completion of the recruitment phase.
Even though the study is not completed yet and data are still blinded, it is of note that there were no serious adverse events so far. Top line data from this study are expected in March 2017, when the post-treatment observation period of all patients will be concluded and data are unblinded.
"After observing very good tolerability of our lead product MP1032 during phase I in healthy volunteers, this good tolerability seems to be confirmed for psoriasis patients." remarked Dr. Wolfgang Brysch, CEO at MetrioPharm AG. "We are on track to conclude the study and look forward to first results on MP1032's efficacy in psoriasis patients. These patients are still in need of a well tolerable oral drug that improves their quality of life. We are working intensely at filling this need."
MP1032 can inhibit inflammation by reducing the concentration of signalling proteins (cytokines) that are involved in the inflammation process in diseases such as chronic plaque psoriasis. MP1032 also has the potential to reduce susceptibility to bacterial and viral infections. MP1032 differs from currently available drugs by its combined anti-inflammatory and anti-infective effect, its efficacy, and good tolerability. Therefore, it has the potential to significantly improve the treatment of psoriasis patients. More than three million people suffer from moderate-to-severe psoriasis in the European Union alone.
A total of 44 male and female participants with chronic plaque psoriasis are enrolled in this clinical trial. Participants are divided into two groups of 22 participants each. Primary endpoints of the study include pharmacokinetics, safety and tolerability of daily doses of MP1032 over six weeks. Preliminary evidence of effectiveness is examined as a secondary endpoint.
More information about this phase IIa clinical trial are available on https://clinicaltrials.gov.
MP1032 targets the molecular activation mechanisms of inflammatory macrophages. These cells drive inflammation, pain and tissue damage in a wide range of inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, musculo-skeletal injuries, and multiple sclerosis.
The lead compound from MetrioPharm's pipeline of patent-protected, small-molecular active substances has strong anti-inflammatory properties and an excellent toxicity profile.
MetrioPharm AG is a pharmaceutical biotech company developing the first effective and safe therapy for chronic immune disorders. Our focus is on Immune-mediated Inflammatory Diseases (IMIDs) such as psoriasis, arthritis and multiple sclerosis. MetrioPharm's lead compound MP1032 is currently in phase II clinical testing.
MetrioPharm AG was founded in 2007. The company is headquartered in Zurich and operates a research facility in Berlin.